Nachrichten zur CymaBay Therapeutics Inc. Aktie

Opthea Appoints Sujal Shah to the Board of Directors

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee…

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)

BALA CYNWYD, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.…

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused…

Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline

Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the…

Arzneimittelentwickler: Pharmakonzern Gilead kauft Cymabay Therapeutics für 4,3 Milliarden Dollar

Cymabay entwickelt Medikamente zur Behandlung von Leberkrankheiten. Der Pharmakonzern Gilead baut mit dem Zukauf nun sein Portfolio aus.…

Gilead Sciences to acquire CymaBay Therapeutics in $4.3bn cash deal By Investing.com

Gilead Sciences to acquire CymaBay Therapeutics in $4.3bn cash deal…

CymaBay Therapeutics to Participate in Upcoming Investment Conferences

NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on…

CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024

NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on…

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused…

Circling Back On CymaBay Therapeutics

…

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused…

CymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Call Transcript

…

CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on…

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused…

CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused…

CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused…

: CymaBay Therapeutics stock jumps as rare liver disease treatment shows positive results

Shares of CymaBay Therapeutics Inc. CBAY gained 23% premarket on Thursday after the company released positive results from a late-stage…

UBS starts Cymabay at buy, expecting positive Phase 3 data for seladelpar

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-Q CymaBay Therapeutics, For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

CymaBay Therapeutics stock price target raised to $16 from $8 at B. Riley

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: President of R&D verkauft Aktien von Cymabay Therapeu im Wert von 248.519$

Mcwherter, Charles - Vorstand - Tag der Transaktion: 2023-07-18...…

Insiderhandel: General Counsel verkauft Aktien von Cymabay Therapeu im Wert von 59.050$

Quinlan, Paul T. - Vorstand - Tag der Transaktion: 2023-07-14...…

Insiderhandel: General Counsel verkauft Aktien von Cymabay Therapeu im Wert von 50.250$

Quinlan, Paul T. - Vorstand - Tag der Transaktion: 2023-06-30...…

Why Shares of CymaBay Therapeutics Are Soaring Friday

A competitors drug had a so-so phase 3 trial, lifting the possibilities for CymaBays lead therapy....…

CymaBay, Cyteir top healthcare gainers; Unicycive, Apyx among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: President of R&D verkauft Aktien von Cymabay Therapeu im Wert von 177.383$

Mcwherter, Charles - Vorstand - Tag der Transaktion: 2023-06-20...…

Form 8-K CymaBay Therapeutics, For: Jun 01

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: President of R&D verkauft Aktien von Cymabay Therapeu im Wert von 197.387$

Mcwherter, Charles - Vorstand - Tag der Transaktion: 2023-05-18...…

Why CymaBay Therapeutics Stock Nose-Dived This Week

Investors did not warmly greet the latest news from the biotech....…

Insiderhandel: General Counsel verkauft Aktien von Cymabay Therapeu im Wert von 51.831$

Quinlan, Paul T. - Vorstand - Tag der Transaktion: 2023-05-15...…

CymaBay Therapeutics GAAP EPS of -$0.29 misses by $0.19

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023

NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused…

CymaBay names new finance chief

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K CymaBay Therapeutics, For: Apr 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on…

dpa-AFX ProFeed